Antidepressants: bleeding or thrombosis?

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Neuroscience

Background:

• Depression contributes to cardiovascular disease through autonomic dysfunction, inflammation, and impaired fibrinolysis.
• Serotonergic antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), may influence cardiovascular risk.
• The precise impact of these antidepressants on thrombotic and cardiovascular events remains debated.

Purpose of the Study:

• To investigate the role of serotonergic antidepressants in cardiovascular disease pathogenesis.
• To elucidate the mechanisms by which these antidepressants affect fibrinolysis and platelet function.
• To reconcile contradictory findings regarding the cardiovascular and thromboembolic risks associated with serotonergic antidepressant use.

Main Methods:

• Review of existing evidence on depression, cardiovascular disease, and serotonergic antidepressants.
• Analysis of the effects of SSRIs and SNRIs on fibrinolytic profiles and platelet aggregation/adhesion.
• Evaluation of studies reporting cardiovascular and thromboembolic outcomes in patients using these medications.

Main Results:

• Serotonergic antidepressants appear to restore fibrinolytic profiles and reduce platelet adhesion to collagen, potentially via interactions with the glycoprotein VI receptor.
• These profibrinolytic and antiplatelet effects may contribute to both reduced thrombotic events and increased bleeding risks (gastrointestinal, intracranial, surgical).
• Contradictory findings exist regarding overall cardiovascular and thromboembolic risk, with some studies showing benefit and others showing increased risk, possibly due to side effects or comorbidities.

Conclusions:

• Serotonergic antidepressants can be considered weak anticoagulants due to their effects on fibrinolysis and platelet adhesion.
• Depressed patients with cardiovascular risk factors should be advised on lifestyle modifications like diet and exercise.
• Further research is needed to fully clarify the complex relationship between serotonergic antidepressants, thrombosis, and cardiovascular outcomes.